Bone Marrow Transplant News and Research

RSS

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

Tennessee Gov. declares February as 'St. Jude Month'

In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile. St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer.

6 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

Alpha-1-antitrypsin may reduce effects of GVHD

A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants.

18 Jan 2012

Ivera receives new FDA clearance for Curos disinfecting port protector

Ivera Medical Corporation today announced it has received a new FDA 510(k) clearance for its Curos disinfecting port protector which reflects the company's ongoing determination to continuously improve its products to better deliver solutions designed to reduce hospital-acquired catheter related bloodstream infections.

18 Jan 2012

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

New findings by St. Michael's researchers about the way cells work could lead to a test and therapy for kidney failure caused by E. coli

11 Jan 2012

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss.

13 Dec 2011

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Move Day at U-M hospitals goes smoothly

Sunday's move from the now former U-M C.S. Mott Children's Hospital, the Von Voigtlander Women's Hospital and the Adult Bone Marrow Transplant Unit to the new facility began at 7:02 a.m. Sunday with a tiny patient - a baby moving from the Neonatal Intensive Care Unit.

6 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

For men older than 50, a simple blood test to screen for prostate cancer is as much a part of annual physicals as weigh-ins and stethoscopes. The PSA test is painless, inexpensive and the only way to detect the disease -; the most common male cancer -; before symptoms turn up.

12 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

29 Sep 2011

Bone Marrow Transplant News and Research

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

Tennessee Gov. declares February as 'St. Jude Month'

Immune cells from healthy individuals effectively kill cancer cells

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Alpha-1-antitrypsin may reduce effects of GVHD

Ivera receives new FDA clearance for Curos disinfecting port protector

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

New cancer research findings presented at 53rd ASH annual meeting

Move Day at U-M hospitals goes smoothly

Treatments for lymphoma with no side effects

GPS at WUSTL now offers new cancer genetic test

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

Potential new drug could treat mixed-lineage leukaemia

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News